0001209191-23-054441.txt : 20231106
0001209191-23-054441.hdr.sgml : 20231106
20231106080010
ACCESSION NUMBER: 0001209191-23-054441
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231103
FILED AS OF DATE: 20231106
DATE AS OF CHANGE: 20231106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: INGRAM DOUGLAS S
CENTRAL INDEX KEY: 0001190644
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 231378158
MAIL ADDRESS:
STREET 1: 2525 DUPONT DR
CITY: IRVINE
STATE: CA
ZIP: 92612
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-03
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001190644
INGRAM DOUGLAS S
215 FIRST STREET, SUITE 415
CAMBRIDGE
MA
02142
1
1
0
0
President & CEO
0
Common Stock
2023-11-03
4
P
0
10081
78.57
A
375163
D
Common Stock
2023-11-03
4
P
0
11060
79.70
A
386223
D
Common Stock
2023-11-03
4
P
0
3884
80.33
A
390107
D
Common Stock
2023-11-03
4
P
0
200
81.26
A
390307
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $78.03 to $79.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.05 to $80.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $80.08 to $80.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
/s/ Ryan Brown, as Attorney-in-Fact for Douglas S. Ingram
2023-11-06